The UPA government’s proposed bid to amend the Right to Information (RTI) Act, in order to avoid compliance with the June 3 CIC order bringing records of political parties within RTI’s ambit, is sparking widespread citizen criticism and mobilisation. (Pl read the links below for more info on RTI and the bid to amend it) An online petition put out by the National Campaign for the People’s Right to Information has...
More »SEARCH RESULT
The poverty quibble-Latha Jishnu
-Down to Earth Government claims a huge drop in poverty numbers but critical indicators-health, malnutrition and wages-continue to be grim. So how did the poor fare better? After a long, long time there was good news to splash as media led with the report of a record 21.9 per cent drop in poverty levels. The July 24 newspaper headlines were celebratory as they reported the Planning Commission's findings that poverty rates...
More »Let’s talk about the growth strategy, stupid -Jayati Ghosh
-Tehelka.com The Sen-Bhagwati ‘debate' on economic policy is focussing on the wrong issues Several things are quite remarkable about the recent debate between Professor Amartya Sen and Professor Jagdish Bhagwati. The first surprise is that such a debate could become a major news item at all, making headlines and filling screen time on news channels, when it is about economic strategies that are normally discussed only in relatively small academic and policy...
More »Bhagwati versus Sen: What's going on?-Mihir S Sharma
-The Business Standard 7 things you should know in the Bhagwati vs Sen slugfest Jagdish Bhagwati and Amartya Sen are the two Indian economists who are most respected for their work. Both have worked on a broad spectrum of issues, though Sen is best known for his work on public choice and development and Bhagwati for his work on trade. They are both liberal, neoclassical economists, who support deregulation and disapprove of...
More »Price control, IP Act & regulatory framework: Revisiting some imp issues about Indian pharma-Ramesh Adige
-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...
More »